Daily2d
GSK Nucala application for COPD accepted for review in China
GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...
Pharmabiz4d
China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease
China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...
GSK announces CNMPA accepted review the new drug application for Nucala
GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...
Investing5d
GSK's Nucala COPD treatment under review in China
The data suggest that Nucala could offer a meaningful benefit to those in need of additional treatments to reduce exacerbation risks. If approved, Nucala would be the first biologic with monthly ...
London South East5d
GSK celebrates Nucala review in China for form of pulmonary disease
(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China ...
Investing5d
GSK's Nucala COPD treatment under review in China
The data suggest that Nucala could offer a meaningful benefit to those in need of additional treatments to reduce exacerbation risks. If approved, Nucala would be the first biologic with monthly ...
GSK Pharma hits 3-month high in weak market; surges 31% in 7 days
The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...
pharmaphorum6d
GSK's Nucala gains US use in rare autoimmune disease
GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...